Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT00761644
Title Doxil, Bevacizumab and Temsirolimus Trial
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

Therapies

Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus

Age Groups: child | adult
Covered Countries USA


No variant requirements are available.